The story so far
India approves first dengue vaccine
Tracked across 3 sources · Updated 2h ago
India's drug regulator DCGI approved Takeda's QDENGA, the first dengue vaccine in the country, for ages 4-60. It requires two doses three months apart without pre-vaccination testing. Rollout expected next year.
How it unfolded
11h ago
Doctors explain vaccine eligibility and efficacy
2d ago
DCGI approves QDENGA, India's first dengue vaccine
What happened earlier
Latest updates
Latest
Full story →India gets its first dengue vaccine: Doctors explain who can take it, how it works and whether it's right for you
India approved QDENGA, developed by Takeda, as its first dengue vaccine for ages 4 to 60.
QDENGA protects against all four dengue virus serotypes and is administered in two doses three months apart.
Clinical studies show QDENGA reduces risk of severe disease and hospitalization but does not guarantee 100% protection.
Mosquito precautions remain essential even after vaccination, doctors emphasize.
People should consult a healthcare provider to determine if QDENGA is appropriate for them.
Earlier · 2d ago
Full story →India approves its first dengue vaccine QDENGA after DCGI clearance
India's drug regulator DCGI approved the first dengue vaccine QDENGA for use in the country.
Dengue is a mosquito-borne disease affecting over 125 countries, with India carrying one-third of the global burden.
QDENGA is given as two subcutaneous injections of 0.5 ml three months apart.
Earlier · 2d ago
Full story →Takeda's dengue vaccine QDENGA gets DCGI approval for use in India
Takeda's dengue vaccine QDENGA has received DCGI approval for use in India.
QDENGA is the first dengue vaccine approved in India, authorised for individuals aged 4-60.
Market authorisation was granted without requiring pre-vaccination testing.
The approval marks a significant step in India's dengue prevention efforts.